Home » Press Releases & Statements » Statement by Research!America President and CEO Mary Woolley on Dr. Robert Califf’s Nomination for FDA Commissioner

Statement by Research!America President and CEO Mary Woolley on Dr. Robert Califf’s Nomination for FDA Commissioner

In nominating Dr. Robert Califf for commissioner of the Food and Drug Administration (FDA), President Biden has made an excellent choice. Research!America strongly supported his nomination in 2015, and we are proud to lend our enthusiastic support once again.

Dr. Califf brings hands-on experience, having served as both Deputy Commissioner and Commissioner of FDA. In addition, his internationally recognized expertise in clinical research, health outcomes assessment, and data science will serve the agency well. He is also a clear communicator who will be able to lead the FDA as it works to synthesize the lessons learned from COVID-19, seeks to deploy the benefits of real-world evidence, and in a myriad of other ways, endeavors to keep pace with rapidly evolving science.

We thank Dr. Janet Woodcock for her service as the FDA’s Acting Commissioner during a critical time for our nation. Her leadership and deep wealth of regulatory expertise were key to bringing about rapid pace interventions against the pandemic.

We urge the Senate to quickly confirm Dr. Califf’s nomination.

Contact Jenny Luray Vice President of Strategy and Communications, at 202-450-9920 or jluray@researchamerica.org with press inquiries.

Home